Immunohistochemistry (IHC) Market - Global Forecast to 2029
出版社 | MarketsandMarkets |
出版年月 | 2024年8月 |
ページ数 | 490 |
図表数 | 729 |
価格 | USD 4,950 |
種別 | 英文調査報告書 |
Report Overview
The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period of 2024 to 2029.
世界の免疫組織化学 (IHC) 市場は、2024年から2029年の予測期間中に7.2%のCAGRで、2024年の37億米ドルから2029年までに52億米ドルに達すると予測されています。
Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology for the development of personalized medicine further support the expansion of the market. Application of IHC in supporting drug development and disease management to improve patient outcomes, along with ongoing research collaboration between pharmaceutical companies and academic institutes provide growth opportunities for players in the Immunohistochemistry Market.

“Histological Stain is expected to account for the largest share of by reagents segment.”
In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains

“Research applications segment accounted for the second-largest share of the application segment.”
In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.
“Asia Pacific is the fastest-growing region in the immunohistochemistry market.”
The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 55%, CXOs – 20%, and Executives – 25%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America- 7%, Middle East and Africa-3%

Prominent Players in the Immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).
Research Coverage:
This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)
- Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the Immunohistochemistry market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.
Table of Contents
1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION 45
1.3 INCLUSIONS AND EXCLUSIONS 46
1.4 STUDY SCOPE 47
1.4.1 SEGMENTS COVERED 47
1.4.2 YEARS CONSIDERED 48
1.4.3 CURRENCY CONSIDERED 48
1.5 STAKEHOLDERS 48
1.6 SUMMARY OF CHANGES 49
2 RESEARCH METHODOLOGY 50
2.1 RESEARCH DATA 50
2.1.1 RESEARCH DESIGN 50
2.1.2 SECONDARY DATA 51
2.1.2.1 Secondary data sources 51
2.1.2.2 Objectives of secondary research 51
2.1.3 PRIMARY DATA 52
2.1.3.1 Objectives of primary research 52
2.2 MARKET SIZE ESTIMATION 53
2.2.1 REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH) 54
2.2.2 INSIGHTS FROM PRIMARIES 55
2.3 MARKET GROWTH FORECAST 56
2.4 DATA TRIANGULATION 58
2.5 STUDY ASSUMPTIONS 58
2.6 RESEARCH LIMITATIONS 59
2.7 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 63
4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND
COUNTRY (2023) 64
4.3 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 64
4.4 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023 65
4.5 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
5.2.1 DRIVERS 67
5.2.1.1 Increasing prevalence of cancer and rising geriatric population 67
5.2.1.2 Technological innovations and advancements in immunohistochemistry diagnostics 70
5.2.1.3 Favorable reimbursement coverage for immunohistochemistry tests 71
5.2.1.4 Growing focus on digital pathology 72
5.2.2 RESTRAINTS 73
5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research 73
5.2.2.2 Highly consolidated market 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 Growing demand for precision/personalized medicines 75
5.2.3.2 Increasing adoption of companion diagnostics 76
5.2.3.3 Growth opportunities in emerging economies 76
5.2.3.4 Integration of AI in immunohistochemistry 77
5.2.4 CHALLENGES 77
5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables 77
5.2.4.2 Lack of standardization 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 78
5.4 PRICING ANALYSIS 78
5.4.1 AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023 79
5.4.2 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 80
5.4.3 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021–2023 80
5.5 TECHNOLOGY ANALYSIS 82
5.5.1 KEY TECHNOLOGIES 83
5.5.1.1 Automated immunohistochemistry systems 83
5.5.1.2 Multiplex immunohistochemistry 83
5.5.2 COMPLEMENTARY TECHNOLOGIES 83
5.5.2.1 Chromogenic detection 83
5.5.2.2 Fluorescent detection 84
5.5.3 ADJACENT TECHNOLOGIES 84
5.5.3.1 In situ hybridization 84
5.6 PATENT ANALYSIS 85
5.6.1 METHODOLOGY 85
5.6.2 INNOVATION AND PATENT APPLICATIONS 85
5.6.3 TOP PATENT APPLICANTS 85
5.7 VALUE CHAIN ANALYSIS 88
5.7.1 RESEARCH & DEVELOPMENT 89
5.7.2 MANUFACTURING 89
5.7.3 LOGISTICS AND POST-SALES 89
5.8 SUPPLY CHAIN ANALYSIS 89
5.9 ECOSYSTEM ANALYSIS 90
5.9.1 ROLE OF RAW MATERIAL SUPPLIERS 91
5.9.2 ROLE OF PRODUCT PROVIDERS 92
5.9.3 ROLE OF END USERS 92
5.9.4 ROLE OF REGULATORY AUTHORITIES 93
5.10 PORTER’S FIVE FORCES ANALYSIS 93
5.10.1 INTENSITY OF COMPETITIVE RIVALRY 94
5.10.2 BARGAINING POWER OF SUPPLIERS 95
5.10.3 BARGAINING POWER OF BUYERS 95
5.10.4 THREAT OF SUBSTITUTES 95
5.10.5 THREAT OF NEW ENTRANTS 96
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 96
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
5.11.2 KEY BUYING CRITERIA 97
5.12 REGULATORY LANDSCAPE 98
5.12.1 REGULATORY ANALYSIS 98
5.12.1.1 North America 98
5.12.1.1.1 US 98
5.12.1.1.2 Canada 100
5.12.1.2 Europe 100
5.12.1.3 Asia Pacific 102
5.12.1.3.1 Japan 102
5.12.1.3.2 China 103
5.12.1.3.3 India 103
5.12.1.4 Latin America 104
5.12.1.4.1 Brazil 104
5.13 KEY CONFERENCES AND EVENTS, 2024–2025 105
5.14 INVESTMENT AND FUNDING SCENARIO 107
5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET 107
6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING 110
6.1 INTRODUCTION 111
6.2 ANTIBODIES 111
6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE 114
6.2.2 PRIMARY ANTIBODIES 114
6.2.2.1 Increasing adoption of targeted immunotherapy to drive segment 114
6.2.3 SECONDARY ANTIBODIES 117
6.2.3.1 Better signal amplification and easier manufacturing process to fuel segment growth 117
6.2.4 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY 120
6.2.5 MONOCLONAL ANTIBODIES 121
6.2.5.1 Increased applications in cancer diagnostics to support market growth 121
6.2.6 POLYCLONAL ANTIBODIES 124
6.2.6.1 Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth 124
6.3 REAGENTS 126
6.3.1 HISTOLOGICAL STAINS 129
6.3.1.1 Growing focus on cancer diagnostics and developmental research to drive segment 129
6.3.2 BLOCKING SERA AND REAGENTS 132
6.3.2.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption 132
6.3.3 CHROMOGENIC SUBSTRATES 135
6.3.3.1 Rapid detection and faster diagnosis to propel segment growth 135
6.3.4 FIXATION REAGENTS 138
6.3.4.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption 138
6.3.5 DILUENTS 141
6.3.5.1 Focus on reducing non-specific background staining during immunostaining to aid segment growth 141
6.3.6 ORGANIC SOLVENTS 144
6.3.6.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market 144
6.3.7 PROTEOLYTIC ENZYMES 146
6.3.7.1 Proteolytic enzymes to improve accessibility of target antibodies 146
6.3.8 OTHER REAGENTS 149
6.4 EQUIPMENT 152
6.4.1 SLIDE-STAINING SYSTEMS 155
6.4.1.1 Availability of technologically advanced slide-staining systems to fuel segment growth 155
6.4.2 TISSUE PROCESSING SYSTEMS 158
6.4.2.1 High equipment cost and need for extensive regulatory compliance to limit market 158
6.4.3 SLIDE SCANNERS 161
6.4.3.1 Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption 161
6.4.4 OTHER EQUIPMENT 164
6.5 KITS 166
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS 170
6.5.1.1 Increasing focus on cancer research to fuel segment growth 170
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS 173
6.5.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth 173
6.6 SOFTWARE 175
6.6.1 GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET 175
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 179
7.1 INTRODUCTION 180
7.2 DIAGNOSTIC APPLICATIONS 180
7.2.1 CANCER 184
7.2.1.1 Increasing target population and rising adoption of targeted therapies to propel market growth 184
7.2.2 INFECTIOUS DISEASES 188
7.2.2.1 High prevalence of infectious diseases and need for early diagnosis to aid market growth 188
7.2.3 NEPHROLOGICAL DISEASES 192
7.2.3.1 Rising prevalence of renal transplant-associated conditions to drive market 192
7.2.4 AUTOIMMUNE DISEASES 195
7.2.4.1 Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth 195
7.2.5 NEUROLOGICAL DISEASES 198
7.2.5.1 Increasing global burden of neurological disorders to spur market growth 198
7.2.6 OTHER DISEASES 201
7.3 RESEARCH APPLICATIONS 204
7.3.1 DRUG DEVELOPMENT AND TESTING 207
7.3.1.1 Need for accurate and objective outcomes in drug testing to augment segment growth 207
7.3.2 OTHER RESEARCH APPLICATIONS 210
7.4 FORENSIC APPLICATIONS 213
7.4.1 INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH 213
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER 216
8.1 INTRODUCTION 217
8.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 217
8.2.1 LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH 217
8.3 ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS 221
8.3.1 GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH 221
8.4 OTHER END USERS 224
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 228
9.1 INTRODUCTION 229
9.2 NORTH AMERICA 229
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 235
9.2.2 US 236
9.2.2.1 US to dominate North American immunohistochemistry market during forecast period 236
9.2.3 CANADA 240
9.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth 240
9.3 EUROPE 244
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 249
9.3.2 GERMANY 250
9.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market 250
9.3.3 UK 254
9.3.3.1 Rising prevalence of cancer and increasing government funding in health research to augment market growth 254
9.3.4 FRANCE 258
9.3.4.1 Increased research in cancer diagnosis and treatment to support market growth 258
9.3.5 ITALY 263
9.3.5.1 Advanced health infrastructure and high geriatric population to
fuel market growth 263
9.3.6 SPAIN 267
9.3.6.1 Increased demand for personalized medicines to boost adoption
of immunohistochemistry products 267
9.3.7 REST OF EUROPE 270
9.4 ASIA PACIFIC 274
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 280
9.4.2 CHINA 281
9.4.2.1 Increasing focus on advanced cancer diagnostics to spur market growth 281
9.4.3 JAPAN 285
9.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth 285
9.4.4 INDIA 289
9.4.4.1 Need for high-end pathology and diagnostic services to propel market growth 289
9.4.5 AUSTRALIA 293
9.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth 293
9.4.6 SOUTH KOREA 297
9.4.6.1 Focus on precision healthcare and personalized medicines to
drive market 297
9.4.7 REST OF ASIA PACIFIC 301
9.5 LATIN AMERICA 305
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 309
9.5.2 BRAZIL 310
9.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth 310
9.5.3 MEXICO 314
9.5.3.1 Increasing research initiatives and rising cancer cases to drive market 314
9.5.4 REST OF LATIN AMERICA 318
9.6 MIDDLE EAST 322
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 326
9.6.2 GCC COUNTRIES 327
9.6.2.1 Saudi Arabia 331
9.6.2.1.1 Growing cancer burden and increasing focus on research to augment market growth 331
9.6.2.2 UAE 334
9.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth 334
9.6.2.3 Rest of GCC Countries 338
9.6.3 REST OF MIDDLE EAST 342
9.7 AFRICA 345
9.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET 345
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 349
10 COMPETITIVE LANDSCAPE 351
10.1 INTRODUCTION 351
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 351
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET 351
10.3 REVENUE ANALYSIS, 2021–2023 353
10.4 MARKET SHARE ANALYSIS, 2023 354
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 356
10.5.1 STARS 356
10.5.2 EMERGING LEADERS 356
10.5.3 PERVASIVE PLAYERS 356
10.5.4 PARTICIPANTS 356
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 358
10.5.5.1 Company footprint 358
10.5.5.2 Offering footprint 359
10.5.5.3 Application footprint 360
10.5.5.4 Region footprint 361
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 362
10.6.1 PROGRESSIVE COMPANIES 362
10.6.2 RESPONSIVE COMPANIES 362
10.6.3 DYNAMIC COMPANIES 362
10.6.4 STARTING BLOCKS 362
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 364
10.7 COMPANY VALUATION AND FINANCIAL METRICS 366
10.7.1 FINANCIAL METRICS 366
10.7.2 COMPANY VALUATION 366
10.8 BRAND/PRODUCT COMPARISON 367
10.9 COMPETITIVE SCENARIO 368
10.9.1 PRODUCT LAUNCHES AND APPROVALS 368
10.9.2 DEALS 369
10.9.3 EXPANSIONS 370
10.9.4 OTHER DEVELOPMENTS 371
11 COMPANY PROFILES 372
11.1 KEY PLAYERS 372
11.1.1 F. HOFFMANN-LA ROCHE LTD. 372
11.1.1.1 Business overview 372
11.1.1.2 Products/Solutions offered 373
11.1.1.3 Recent developments 377
11.1.1.3.1 Product launches and approvals 377
11.1.1.3.2 Deals 379
11.1.1.4 MnM view 380
11.1.1.4.1 Key strengths 380
11.1.1.4.2 Strategic choices 380
11.1.1.4.3 Weaknesses and competitive threats 380
11.1.2 DANAHER CORPORATION 381
11.1.2.1 Business overview 381
11.1.2.2 Products/Solutions offered 382
11.1.2.3 Recent developments 386
11.1.2.3.1 Product launches and approvals 386
11.1.2.3.2 Deals 386
11.1.2.4 MnM view 387
11.1.2.4.1 Key strengths 387
11.1.2.4.2 Strategic choices 387
11.1.2.4.3 Weaknesses and competitive threats 387
11.1.3 AGILENT TECHNOLOGIES, INC. 388
11.1.3.1 Business overview 388
11.1.3.2 Products/Solutions offered 389
11.1.3.3 Recent developments 393
11.1.3.3.1 Product launches and approvals 393
11.1.3.3.2 Deals 394
11.1.3.3.3 Expansions 394
11.1.3.4 MnM view 395
11.1.3.4.1 Key strengths 395
11.1.3.4.2 Strategic choices 395
11.1.3.4.3 Weaknesses and competitive threats 395
11.1.4 PHC HOLDINGS CORPORATION 396
11.1.4.1 Business overview 396
11.1.4.2 Products/Solutions offered 397
11.1.4.3 Recent developments 402
11.1.4.3.1 Deals 402
11.1.4.3.2 Other developments 403
11.1.4.4 MnM view 403
11.1.4.4.1 Key strengths 403
11.1.4.4.2 Strategic choices 403
11.1.4.4.3 Weaknesses and competitive threats 403
11.1.5 THERMO FISHER SCIENTIFIC INC. 404
11.1.5.1 Business overview 404
11.1.5.2 Products/Solutions offered 405
11.1.6 MERCK KGAA 409
11.1.6.1 Business overview 409
11.1.6.2 Products/Solutions offered 410
11.1.7 BIO-RAD LABORATORIES, INC. 417
11.1.7.1 Business overview 417
11.1.7.2 Products/Solutions offered 418
11.1.8 BIO-TECHNE 422
11.1.8.1 Business overview 422
11.1.8.2 Products/Solutions offered 423
11.1.8.3 Recent developments 426
11.1.8.3.1 Deals 426
11.1.8.3.2 Expansions 426
11.1.8.3.3 Other developments 426
11.1.9 BECTON, DICKINSON AND COMPANY 427
11.1.9.1 Business overview 427
11.1.9.2 Products/Solutions offered 428
11.1.9.3 Recent developments 432
11.1.9.3.1 Expansions 432
11.1.10 TAKARA BIO INC. 433
11.1.10.1 Business overview 433
11.1.10.2 Products/Solutions offered 434
11.1.11 ENZO BIOCHEM INC. 438
11.1.11.1 Business overview 438
11.1.11.2 Products/Solutions offered 439
11.1.11.3 Recent developments 441
11.1.11.3.1 Expansions 441
11.1.12 SINO BIOLOGICAL, INC. 442
11.1.12.1 Business overview 442
11.1.12.2 Products/Solutions offered 442
11.1.12.3 Recent developments 443
11.1.12.3.1 Expansions 443
11.1.13 SAKURA FINETEK JAPAN CO., LTD. 444
11.1.13.1 Business overview 444
11.1.13.2 Products/Solutions offered 444
11.1.13.3 Recent developments 447
11.1.13.3.1 Product launches 447
11.1.13.3.2 Deals 449
11.1.14 CELL SIGNALING TECHNOLOGY, INC. 450
11.1.14.1 Business overview 450
11.1.14.2 Products/Solutions offered 450
11.1.14.3 Recent developments 453
11.1.14.3.1 Deals 453
11.1.15 BIO SB 454
11.1.15.1 Business overview 454
11.1.15.2 Products/Solutions offered 454
11.1.15.3 Recent developments 459
11.1.15.3.1 Product launches 459
11.1.16 MILTENYI BIOTEC 460
11.1.16.1 Business overview 460
11.1.16.2 Products/Solutions offered 460
11.1.17 ORIGENE TECHNOLOGIES, INC. 463
11.1.17.1 Business overview 463
11.1.17.2 Products/Solutions offered 463
11.2 OTHER PLAYERS 468
11.2.1 EAGLEBIO 468
11.2.2 BIOCARE MEDICAL, LLC 469
11.2.3 ELABSCIENCE BIONOVATION INC. 471
11.2.4 BIOGENEX 473
11.2.5 DIAGNOSTIC BIOSYSTEMS INC. 475
11.2.6 HISTO-LINE LABORATORIES 477
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC. 479
11.2.8 CANDOR BIOSCIENCE GMBH 480
11.2.9 GENEMED BIOTECHNOLOGIES, INC. 481
12 APPENDIX 482
12.1 DISCUSSION GUIDE 482
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 486
12.3 CUSTOMIZATION OPTIONS 488
12.4 RELATED REPORTS 488
12.5 AUTHOR DETAILS 489
LIST OF TABLES
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS AND EXCLUSIONS 46
TABLE 2 IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS 67
TABLE 3 ESTIMATED NUMBER OF NEW CASES, BY REGION, 2022–2045 (THOUSAND) 68
TABLE 4 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION,
BY REGION, 2022–2050 69
TABLE 5 CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES 71
TABLE 6 MAJOR ACQUISITIONS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2023 74
TABLE 7 AVERAGE SELLING PRICE FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2023 79
TABLE 8 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 (USD) 80
TABLE 9 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS,
BY REGION, 2021–2023 (USD) 80
TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 85
TABLE 11 TOP 20 PATENT OWNERS IN IMMUNOHISTOCHEMISTRY MARKET, 2014–2024 86
TABLE 12 INDICATIVE LIST OF PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2022–2024 87
TABLE 13 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF RAW MATERIAL SUPPLIERS 91
TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF PRODUCT PROVIDERS 92
TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF END USERS 92
TABLE 16 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF REGULATORY AUTHORITIES 93
TABLE 17 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS 93
TABLE 18 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY END USER 97
TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 98
TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 100
TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 102
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103
TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103
TABLE 24 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY CONFERENCES
AND EVENTS, JANUARY 2024–DECEMBER 2025 105
TABLE 25 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 111
TABLE 26 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION,
2022–2029 (USD MILLION) 112
TABLE 27 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 28 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 29 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 30 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 31 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 32 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 33 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 114
TABLE 34 PRIMARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 115
TABLE 35 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 36 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 116
TABLE 37 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 116
TABLE 38 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 116
TABLE 39 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 117
TABLE 40 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 117
TABLE 41 SECONDARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 118
TABLE 42 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 118
TABLE 43 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 44 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 45 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 46 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 120
TABLE 47 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 120
TABLE 48 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 120
TABLE 49 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 50 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 51 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 52 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 53 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 54 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 55 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 56 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 57 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 58 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 59 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 60 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 61 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 126
TABLE 62 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 126
TABLE 63 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 127
TABLE 64 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION) 127
TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 127
TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 128
TABLE 67 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 128
TABLE 68 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 69 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 70 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 71 HISTOLOGICAL STAINS MARKET, BY REGION, 2022–2029 (USD MILLION) 130
TABLE 72 NORTH AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 130
TABLE 73 EUROPE: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 74 ASIA PACIFIC: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 75 LATIN AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 76 MIDDLE EAST: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 132
TABLE 77 GCC COUNTRIES: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 132
TABLE 78 BLOCKING SERA AND REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION) 133
TABLE 79 NORTH AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 80 EUROPE: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 81 ASIA PACIFIC: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 134
TABLE 82 LATIN AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 134
TABLE 83 MIDDLE EAST: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 134
TABLE 84 GCC COUNTRIES: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 135
TABLE 85 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2022–2029 (USD MILLION) 136
TABLE 86 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 136
TABLE 87 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 136
TABLE 88 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 137
TABLE 89 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 137
TABLE 90 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 137
TABLE 91 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 138
TABLE 92 FIXATION REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 93 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 139
TABLE 94 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 95 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 140
TABLE 96 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 140
TABLE 97 MIDDLE EAST: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 140
TABLE 98 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 141
TABLE 99 DILUENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 100 NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 101 EUROPE: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 102 ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 103 LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 104 MIDDLE EAST: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 105 GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 106 ORGANIC SOLVENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 107 NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 144
TABLE 108 EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 109 ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 145
TABLE 110 LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 145
TABLE 111 MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 146
TABLE 112 GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 146
TABLE 113 PROTEOLYTIC ENZYMES MARKET, BY REGION, 2022–2029 (USD MILLION) 147
TABLE 114 NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 147
TABLE 115 EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 147
TABLE 116 ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 148
TABLE 117 LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 148
TABLE 118 MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 148
TABLE 119 GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 120 OTHER REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 121 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 150
TABLE 122 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 123 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 151
TABLE 124 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 151
TABLE 125 MIDDLE EAST: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 151
TABLE 126 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 152
TABLE 127 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 152
TABLE 128 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION) 153
TABLE 129 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 130 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 153
TABLE 131 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 132 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 133 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 134 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 135 IMMUNOHISTOCHEMISTRY SLIDE-STAINING SYSTEMS MARKET, BY VOLUME, 2022–2029 (UNITS) 155
TABLE 136 SLIDE-STAINING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 137 NORTH AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 156
TABLE 138 EUROPE: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 156
TABLE 139 ASIA PACIFIC: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 157
TABLE 140 LATIN AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 157
TABLE 141 MIDDLE EAST: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 157
TABLE 142 GCC COUNTRIES: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 158
TABLE 143 TISSUE PROCESSING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION) 158
TABLE 144 NORTH AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 159
TABLE 145 EUROPE: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 159
TABLE 146 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 159
TABLE 147 LATIN AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 160
TABLE 148 MIDDLE EAST: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 160
TABLE 149 GCC COUNTRIES: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 160
TABLE 150 SLIDE SCANNERS MARKET, BY REGION, 2022–2029 (USD MILLION) 161
TABLE 151 NORTH AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 162
TABLE 152 EUROPE: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 153 ASIA PACIFIC: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 162
TABLE 154 LATIN AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 163
TABLE 155 MIDDLE EAST: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 163
TABLE 156 GCC COUNTRIES: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 163
TABLE 157 OTHER EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 158 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 164
TABLE 159 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 160 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 165
TABLE 161 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 165
TABLE 162 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 166
TABLE 163 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 166
TABLE 164 IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 165 IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION) 167
TABLE 166 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 167
TABLE 167 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 168
TABLE 168 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 168
TABLE 169 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 169
TABLE 170 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 169
TABLE 171 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 169
TABLE 172 HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,
2022–2029 (USD MILLION) 170
TABLE 173 NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 174 EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 171
TABLE 175 ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 176 LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 177 MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 178 GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 179 ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,
2022–2029 (USD MILLION) 173
TABLE 180 NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 181 EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 174
TABLE 182 ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 183 LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 184 MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 185 GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 186 IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY REGION,
2022–2029 (USD MILLION) 176
TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 188 EUROPE: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 176
TABLE 189 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 190 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 191 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 192 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 193 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 180
TABLE 194 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 181
TABLE 195 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION) 181
TABLE 196 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 197 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 199 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 200 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 201 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 202 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 184
TABLE 203 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER,
BY REGION, 2022–2029 (USD MILLION) 186
TABLE 204 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 206 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 207 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 208 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 209 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 210 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 189
TABLE 211 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR
INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 189
TABLE 212 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 214 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 215 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 216 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 217 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 218 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 192
TABLE 219 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 220 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 221 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 222 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 223 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 224 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 225 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION) 195
TABLE 226 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 227 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 228 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 229 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 230 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 231 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 232 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR NEUROLOGICAL DISEASES 198
TABLE 233 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 199
TABLE 234 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 235 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 236 ASIA PACIFIC: I IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 237 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 238 MIDDLE EAST IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 239 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 240 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR
OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION) 201
TABLE 241 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 242 EUROPE IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 243 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 244 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 245 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 246 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 247 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 204
TABLE 248 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION) 204
TABLE 249 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 250 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 251 ASIA PACIFIC IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 252 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 253 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 254 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 255 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY REGION, 2022–2029 (USD MILLION) 208
TABLE 256 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION) 208
TABLE 257 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 259 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION) 209
TABLE 260 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 261 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION) 210
TABLE 262 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR
OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 210
TABLE 263 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 264 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 266 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 267 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 268 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 269 IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION,
2022–2029 (USD MILLION) 213
TABLE 270 NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 271 EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 214
TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 214
TABLE 273 LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 274 MIDDLE EAST: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 275 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 276 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION) 217
TABLE 277 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 218
TABLE 278 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS
AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 279 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND
DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 280 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 281 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 220
TABLE 282 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 220
TABLE 283 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 220
TABLE 284 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION) 221
TABLE 285 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 222
TABLE 286 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION) 222
TABLE 287 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION) 223
TABLE 288 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION) 223
TABLE 289 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION) 223
TABLE 290 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 224
TABLE 291 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION) 225
TABLE 292 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 293 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 294 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 295 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 296 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 297 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 227
TABLE 298 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2022–2029 (USD MILLION) 229
TABLE 299 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 231
TABLE 300 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 231
TABLE 301 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 302 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 232
TABLE 303 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 304 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 305 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 233
TABLE 306 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 233
TABLE 307 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 308 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 309 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 234
TABLE 310 NORTH AMERICA: KEY MACROINDICATORS 235
TABLE 311 US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET 236
TABLE 312 US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 237
TABLE 313 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 237
TABLE 314 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 238
TABLE 315 US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 238
TABLE 316 US: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 238
TABLE 317 US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 239
TABLE 318 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 239
TABLE 319 US: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 320 US: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 321 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 240
TABLE 322 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 241
TABLE 323 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 241
TABLE 324 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 241
TABLE 325 CANADA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 242
TABLE 326 CANADA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 242
TABLE 327 CANADA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 243
TABLE 328 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 243
TABLE 329 CANADA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 330 CANADA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 331 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 244
TABLE 332 EUROPE: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET 245
TABLE 333 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 245
TABLE 334 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 246
TABLE 335 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 246
TABLE 336 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 246
TABLE 337 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 247
TABLE 338 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 247
TABLE 339 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 248
TABLE 340 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 248
TABLE 341 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 342 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 343 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 249
TABLE 344 EUROPE: KEY MACROINDICATORS 250
TABLE 345 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 251
TABLE 346 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 251
TABLE 347 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 252
TABLE 348 GERMANY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 252
TABLE 349 GERMANY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 252
TABLE 350 GERMANY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 253
TABLE 351 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 253
TABLE 352 GERMANY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 353 GERMANY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 354 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 254
TABLE 355 UK: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 255
TABLE 356 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 255
TABLE 357 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 256
TABLE 358 UK: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 359 UK: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 360 UK: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 257
TABLE 361 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 257
TABLE 362 UK: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 363 UK: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 364 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 258
TABLE 365 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 259
TABLE 366 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 259
TABLE 367 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 260
TABLE 368 FRANCE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 260
TABLE 369 FRANCE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 261
TABLE 370 FRANCE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 261
TABLE 371 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 261
TABLE 372 FRANCE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 373 FRANCE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 374 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 262
TABLE 375 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 263
TABLE 376 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 263
TABLE 377 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 264
TABLE 378 ITALY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 264
TABLE 379 ITALY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 265
TABLE 380 ITALY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 265
TABLE 381 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 265
TABLE 382 ITALY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 383 ITALY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 384 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 266
TABLE 385 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 267
TABLE 386 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 267
TABLE 387 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 268
TABLE 388 SPAIN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 268
TABLE 389 SPAIN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 268
TABLE 390 SPAIN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 269
TABLE 391 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 269
TABLE 392 SPAIN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 393 SPAIN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 270
TABLE 394 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 270
TABLE 395 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 271
TABLE 396 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 271
TABLE 397 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 271
TABLE 398 REST OF EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 399 REST OF EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 400 REST OF EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 273
TABLE 401 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 273
TABLE 402 REST OF EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 403 REST OF EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 404 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 274
TABLE 405 ASIA PACIFIC: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET 275
TABLE 406 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 276
TABLE 407 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 276
TABLE 408 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 277
TABLE 409 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 277
TABLE 410 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 277
TABLE 411 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 278
TABLE 412 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 278
TABLE 413 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 278
TABLE 414 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 415 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 416 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 279
TABLE 417 ASIA PACIFIC: KEY MACROINDICATORS 281
TABLE 418 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 282
TABLE 419 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 282
TABLE 420 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 283
TABLE 421 CHINA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 283
TABLE 422 CHINA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 283
TABLE 423 CHINA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 284
TABLE 424 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 284
TABLE 425 CHINA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 426 CHINA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 427 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 285
TABLE 428 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 286
TABLE 429 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 286
TABLE 430 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 286
TABLE 431 JAPAN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 287
TABLE 432 JAPAN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 287
TABLE 433 JAPAN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 287
TABLE 434 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 288
TABLE 435 JAPAN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 288
TABLE 436 JAPAN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 288
TABLE 437 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 289
TABLE 438 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 290
TABLE 439 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 290
TABLE 440 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 290
TABLE 441 INDIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 291
TABLE 442 INDIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 291
TABLE 443 INDIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 292
TABLE 444 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 292
TABLE 445 INDIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 446 INDIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 293
TABLE 447 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 293
TABLE 448 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 294
TABLE 449 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 294
TABLE 450 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 295
TABLE 451 AUSTRALIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 295
TABLE 452 AUSTRALIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 295
TABLE 453 AUSTRALIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 296
TABLE 454 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 296
TABLE 455 AUSTRALIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 296
TABLE 456 AUSTRALIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 457 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 297
TABLE 458 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 298
TABLE 459 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 298
TABLE 460 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 298
TABLE 461 SOUTH KOREA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 299
TABLE 462 SOUTH KOREA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 299
TABLE 463 SOUTH KOREA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 300
TABLE 464 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 300
TABLE 465 SOUTH KOREA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 466 SOUTH KOREA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 301
TABLE 467 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 301
TABLE 468 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 302
TABLE 469 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 470 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,
BY CLONALITY, 2022–2029 (USD MILLION) 303
TABLE 471 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 303
TABLE 472 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 303
TABLE 473 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 304
TABLE 474 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 304
TABLE 475 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 304
TABLE 476 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 305
TABLE 477 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 305
TABLE 478 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 306
TABLE 479 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 306
TABLE 480 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 306
TABLE 481 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 307
TABLE 482 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 307
TABLE 483 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 307
TABLE 484 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 308
TABLE 485 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 308
TABLE 486 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 308
TABLE 487 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 309
TABLE 488 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 309
TABLE 489 LATIN AMERICA: KEY MACROINDICATORS 310
TABLE 490 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 311
TABLE 491 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 311
TABLE 492 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 311
TABLE 493 BRAZIL: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 312
TABLE 494 BRAZIL: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 312
TABLE 495 BRAZIL: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 313
TABLE 496 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 313
TABLE 497 BRAZIL: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 313
TABLE 498 BRAZIL: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 314
TABLE 499 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 314
TABLE 500 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 315
TABLE 501 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 315
TABLE 502 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 315
TABLE 503 MEXICO: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 316
TABLE 504 MEXICO: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 316
TABLE 505 MEXICO: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 316
TABLE 506 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 317
TABLE 507 MEXICO: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 317
TABLE 508 MEXICO: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 317
TABLE 509 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 318
TABLE 510 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 318
TABLE 511 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 319
TABLE 512 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,
BY CLONALITY, 2022–2029 (USD MILLION) 319
TABLE 513 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 319
TABLE 514 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET,
BY TYPE, 2022–2029 (USD MILLION) 320
TABLE 515 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION) 320
TABLE 516 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 320
TABLE 517 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 321
TABLE 518 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 321
TABLE 519 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION) 321
TABLE 520 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 322
TABLE 521 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 322
TABLE 522 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 323
TABLE 523 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 323
TABLE 524 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 323
TABLE 525 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 324
TABLE 526 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 324
TABLE 527 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 324
TABLE 528 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 325
TABLE 529 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 325
TABLE 530 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 325
TABLE 531 MIDDLE EAST: KEY MACROINDICATORS 326
TABLE 532 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 327
TABLE 533 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 327
TABLE 534 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 328
TABLE 535 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION) 328
TABLE 536 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 328
TABLE 537 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 329
TABLE 538 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 329
TABLE 539 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 329
TABLE 540 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 330
TABLE 541 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 330
TABLE 542 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 330
TABLE 543 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 331
TABLE 544 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 331
TABLE 545 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 332
TABLE 546 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 332
TABLE 547 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 332
TABLE 548 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 333
TABLE 549 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 333
TABLE 550 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 333
TABLE 551 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 334
TABLE 552 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 334
TABLE 553 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 335
TABLE 554 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 335
TABLE 555 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 335
TABLE 556 UAE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 336
TABLE 557 UAE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 336
TABLE 558 UAE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 336
TABLE 559 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 337
TABLE 560 UAE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 337
TABLE 561 UAE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 337
TABLE 562 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 338
TABLE 563 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 338
TABLE 564 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 339
TABLE 565 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,
BY CLONALITY, 2022–2029 (USD MILLION) 339
TABLE 566 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 339
TABLE 567 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET,
BY TYPE, 2022–2029 (USD MILLION) 340
TABLE 568 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION) 340
TABLE 569 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 340
TABLE 570 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 341
TABLE 571 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 341
TABLE 572 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION) 341
TABLE 573 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 342
TABLE 574 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 342
TABLE 575 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,
BY CLONALITY, 2022–2029 (USD MILLION) 343
TABLE 576 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 343
TABLE 577 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 343
TABLE 578 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 344
TABLE 579 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 344
TABLE 580 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 344
TABLE 581 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 345
TABLE 582 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION) 345
TABLE 583 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 346
TABLE 584 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION) 346
TABLE 585 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION) 346
TABLE 586 AFRICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 347
TABLE 587 AFRICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 347
TABLE 588 AFRICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION) 348
TABLE 589 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 348
TABLE 590 AFRICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 348
TABLE 591 AFRICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 349
TABLE 592 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION) 349
TABLE 593 AFRICA: KEY MACROINDICATORS 350
TABLE 594 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET 351
TABLE 595 IMMUNOHISTOCHEMISTRY MARKET: DEGREE OF COMPETITION 354
TABLE 596 IMMUNOHISTOCHEMISTRY MARKET: OFFERING FOOTPRINT 359
TABLE 597 IMMUNOHISTOCHEMISTRY MARKET: APPLICATION FOOTPRINT 360
TABLE 598 IMMUNOHISTOCHEMISTRY MARKET: REGION FOOTPRINT 361
TABLE 599 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF
KEY STARTUP/SME PLAYERS 364
TABLE 600 IMMUNOHISTOCHEMISTRY MARKET: COMPETITIVE BENCHMARKING OF
KEY EMERGING PLAYERS/STARTUPS 365
TABLE 601 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES AND
APPROVALS, JANUARY 2021–JULY 2024 368
TABLE 602 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2021–JULY 2024 369
TABLE 603 IMMUNOHISTOCHEMISTRY MARKET: EXPANSIONS, JANUARY 2021–JULY 2024 370
TABLE 604 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–JULY 2024 371
TABLE 605 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 372
TABLE 606 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SOLUTIONS OFFERED 373
TABLE 607 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–JULY 2024 377
TABLE 608 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JULY 2024 379
TABLE 609 DANAHER CORPORATION: COMPANY OVERVIEW 381
TABLE 610 DANAHER CORPORATION: PRODUCTS/SOLUTIONS OFFERED 382
TABLE 611 DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–JULY 2024 386
TABLE 612 DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2024 386
TABLE 613 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 388
TABLE 614 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED 389
TABLE 615 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–JULY 2024 393
TABLE 616 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–JULY 2024 394
TABLE 617 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–JULY 2024 394
TABLE 618 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW 396
TABLE 619 PHC HOLDINGS CORPORATION: PRODUCTS/SOLUTIONS OFFERED 397
TABLE 620 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2021– JULY 2024 402
TABLE 621 PHC HOLDINGS CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2021–JULY 2024 403
TABLE 622 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 404
TABLE 623 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SOLUTIONS OFFERED 405
TABLE 624 MERCK KGAA: COMPANY OVERVIEW 409
TABLE 625 MERCK KGAA: PRODUCTS/SOLUTIONS OFFERED 410
TABLE 626 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 417
TABLE 627 BIO-RAD LABORATORIES, INC.: PRODUCTS/SOLUTIONS OFFERED 418
TABLE 628 BIO-TECHNE: COMPANY OVERVIEW 422
TABLE 629 BIO-TECHNE: PRODUCTS/SOLUTIONS OFFERED 423
TABLE 630 BIO-TECHNE: DEALS, JANUARY 2021– JULY 2024 426
TABLE 631 BIO-TECHNE: EXPANSIONS, JANUARY 2021– JULY 2024 426
TABLE 632 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021– JULY 2024 426
TABLE 633 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 427
TABLE 634 BECTON, DICKINSON AND COMPANY: PRODUCTS/SOLUTIONS OFFERED 428
TABLE 635 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2021– JULY 2024 432
TABLE 636 TAKARA BIO INC.: COMPANY OVERVIEW 433
TABLE 637 TAKARA BIO INC.: PRODUCTS/SOLUTIONS OFFERED 434
TABLE 638 ENZO BIOCHEM INC.: COMPANY OVERVIEW 438
TABLE 639 ENZO BIOCHEM INC.: PRODUCTS/SOLUTIONS OFFERED 439
TABLE 640 ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021–JULY 2024 441
TABLE 641 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 442
TABLE 642 SINO BIOLOGICAL, INC.: PRODUCTS/SOLUTIONS OFFERED 442
TABLE 643 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021–JULY 2024 443
TABLE 644 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW 444
TABLE 645 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS/SOLUTIONS OFFERED 444
TABLE 646 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES,
JANUARY 2021–JULY 2024 447
TABLE 647 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2021–JULY 2024 449
TABLE 648 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 450
TABLE 649 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SOLUTIONS OFFERED 450
TABLE 650 CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2021–JULY 2024 453
TABLE 651 BIO SB: COMPANY OVERVIEW 454
TABLE 652 BIO SB: PRODUCTS/SOLUTIONS OFFERED 454
TABLE 653 BIO SB: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024 459
TABLE 654 MILTENYI BIOTEC: COMPANY OVERVIEW 460
TABLE 655 MILTENYI BIOTEC: PRODUCTS/SOLUTIONS OFFERED 460
TABLE 656 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 463
TABLE 657 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED 463
TABLE 658 EAGLEBIO: COMPANY OVERVIEW 468
TABLE 659 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW 469
TABLE 660 ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW 471
TABLE 661 BIOGENEX: COMPANY OVERVIEW 473
TABLE 662 DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW 475
TABLE 663 HISTO-LINE LABORATORIES: COMPANY OVERVIEW 477
TABLE 664 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW 479
TABLE 665 CANDOR BIOSCIENCE GMBH: COMPANY OVERVIEW 480
TABLE 666 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 481
LIST OF FIGURES
FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET: SEGMENTS & REGIONS COVERED 47
FIGURE 2 IMMUNOHISTOCHEMISTRY MARKET: YEARS CONSIDERED 48
FIGURE 3 IMMUNOHISTOCHEMISTRY MARKET: RESEARCH DESIGN 50
FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET: BREAKDOWN OF PRIMARIES 52
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2023) 53
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023) 53
FIGURE 7 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE LTD.:
REVENUE SHARE ANALYSIS (2023) 54
FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS 55
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 55
FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTION, 2024–2029 57
FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET: GROWTH ANALYSIS OF
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
FIGURE 12 DATA TRIANGULATION METHODOLOGY 58
FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 60
FIGURE 14 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2024 VS. 2029 (USD MILLION) 61
FIGURE 15 IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 61
FIGURE 16 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT 62
FIGURE 17 GROWING PREVALENCE OF CANCER AND INCREASING
HEALTHCARE EXPENDITURE TO DRIVE MARKET 63
FIGURE 18 US AND DIAGNOSTIC APPLICATIONS DOMINATED NORTH AMERICAN MARKET
IN 2023 64
FIGURE 19 ANTIBODIES TO DOMINATE IMMUNOHISTOCHEMISTRY MARKET IN 2029 64
FIGURE 20 HOSPITALS AND DIAGNOSTIC LABORATORIES ACCOUNTED FOR
LARGEST MARKET SHARE IN 2023 65
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 65
FIGURE 22 IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 66
FIGURE 23 RATE OF CANCER INCIDENCE, BY REGION AND CANCER TYPE (2022) 68
FIGURE 24 SHARE OF PERSONALIZED MEDICINES APPROVED BY FDA (2015–2023) 75
FIGURE 25 IMMUNOHISTOCHEMISTRY MARKET:
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 78
FIGURE 26 AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 81
FIGURE 27 AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY
CONSUMABLES, 2021–2023 82
FIGURE 28 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024 85
FIGURE 29 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS,
2014–2024 86
FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING PHASE 88
FIGURE 31 IMMUNOHISTOCHEMISTRY MARKET: SUPPLY CHAIN ANALYSIS 89
FIGURE 32 IMMUNOHISTOCHEMISTRY MARKET: ECOSYSTEM ANALYSIS 91
FIGURE 33 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS 94
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS 96
FIGURE 35 KEY BUYING CRITERIA FOR END USERS 97
FIGURE 36 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99
FIGURE 37 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100
FIGURE 38 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 101
FIGURE 39 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102
FIGURE 40 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104
FIGURE 41 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 105
FIGURE 42 IMMUNOHISTOCHEMISTRY MARKET: IMPACT OF AI/GEN AI 108
FIGURE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023) 230
FIGURE 44 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023) 275
FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2021–2023) 353
FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN
IMMUNOHISTOCHEMISTRY MARKET (2023) 354
FIGURE 47 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 357
FIGURE 48 IMMUNOHISTOCHEMISTRY MARKET: COMPANY FOOTPRINT 358
FIGURE 49 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 363
FIGURE 50 PRICE-TO-EARNINGS(P/E) RATIO OF KEY VENDORS 366
FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 366
FIGURE 52 IMMUNOHISTOCHEMISTRY MARKET: BRAND/COMPARISON 367
FIGURE 53 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 373
FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 382
FIGURE 55 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 389
FIGURE 56 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023) 397
FIGURE 57 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2023) 405
FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023) 410
FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 418
FIGURE 60 BIO-TECHNE: COMPANY SNAPSHOT (2023) 423
FIGURE 61 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 428
FIGURE 62 TAKARA BIO INC.: COMPANY SNAPSHOT (2023) 434
FIGURE 63 ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2023) 438
MarketsandMarkets(マーケッツアンドマーケッツ)は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間~12時間以内(営業日基準)にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
シングルユーザ | コーポレート |
USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨(定価)を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料(ハンドリングチャージ)無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内(関連会社除く)5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100%持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内(営業日基準)
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 栄養補助食品用包装市場 – 2030年までの世界予測 2025-04-07
- 産業用ボイラー市場 – 2030年までの世界予測 2025-04-04
- オープンギア用潤滑油市場 – 2030年までの世界予測 2025-04-04
- 建設重機市場 – 2030年までの世界予測 2025-04-03
- 従来の創傷ケア市場 – 2030年までの世界予測 2025-04-02